Syntara outlines strong clinical progress in blood cancer program - Sharecafe
Syntara Reports Strong Clinical Progress in Blood Cancer Program Syntara (ASX:SNT) is advancing multiple Phase 2 studies with its lead drug amsulostat, showing promising results in myelofi…